Ascensia Diabetes Care parent company PHC Holdings and Senseonics announced today that Ascensia named Brian Hansen its president of CGM.
Hansen’s appointment to the newly created role at the global distributor of Senseonics’ Eversense CGM went into effect today, Feb. 6.
Responsibilities for Hansen include the global commercialization and growth of the Eversense system. The fully implantable CGM allows for the continuous measurement of glucose levels for up to six months. With longevity, it also offers features like a removable transmitter, discreet on-body vibe alerts, accuracy and a smartphone app.
Hansen previously served as chief commercial officer at insulin pump maker Tandem Diabetes Care. He also held leadership positions at Adaptive Biotechnologies, Genoptix, Gen Probe and Thermo Fisher Scientific.
“Our commercialization of Eversense is building momentum as we work to drive more and more awareness of the unique benefits of Eversense. We look forward to welcoming Brian to our motivated and passionate team, and expect his wealth of experience delivering breakthrough diabetes devices will help us to unleash Eversense’s full commercial potential,” said Robert Schumm, president of Ascensia.
In addition to Eversense, Ascensia makes the Contour portfolio of blood glucose monitoring (BGM) systems. Schumm plans ton continue in his current role while shifting focus to that BGM business.
Senseonics expects to provide a full-year growth outlook in the second quarter, once Hansen assesses the current commercial plan.
“We are thrilled that Ascensia has built out a dedicated CGM arm to drive patient and provider adoption of Eversense. This is a testament to our partnership and the ongoing collaboration between PHCHD, Ascensia and Senseonics. We look forward to working with Brian and leveraging his extensive industry experience to catalyze the next phase of growth for Eversense,” said Senseonics CEO Tim Goodnow. “Together our top priority will be evaluating and optimizing the strategy to deliver the benefits of Eversense to the most patients globally as we work to advance the revolutionary 365-day system to the market.”
